ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Derendorf, H.
Right arrow Articles by Wurst, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Derendorf, H.
Right arrow Articles by Wurst, W.
Eur Respir J 2006; 28:1042-1050
Copyright ©ERS Journals Ltd 2006

Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma

H. Derendorf1, R. Nave2, A. Drollmann2, F. Cerasoli3 and W. Wurst2

2 ALTANA Pharma, Konstanz, Germany. 1 Dept of Pharmaceutics, University of Florida College of Pharmacy, Gainesville, FL, and 3 ALTANA Pharma, Florham Park, NJ, USA.

CORRESPONDENCE: H. Derendorf, Dept of Pharmaceutics, University of Florida, 100494 College of Pharmacy, Gainesville, FL 32610, USA. Fax: 1 3523923249. E-mail: hartmut{at}cop.ufl.edu

Keywords: Ciclesonide, clinical relevance, cortisol, lipid conjugation, on-site activation, side-effects

Received: June 27, 2005
Accepted June 21, 2006

The pharmacokinetic and pharmacodynamic effects of inhaled corticosteroids (ICS) have shaped the efficacy and safety of these agents in the treatment of asthma.

Important pharmacokinetic and pharmacodynamic characteristics that can enhance the efficacy of ICS include small particle size, high glucocorticoid-receptor-binding affinity, long pulmonary residence time and lipid conjugation. These characteristics can increase or prolong the anti-inflammatory effects of an ICS. Important pharmacokinetic characteristics that can enhance the safety of ICS include on-site activation in the lung, low oropharyngeal exposure, negligible oral bioavailability, high protein-binding and rapid systemic clearance.

The degree of oropharyngeal exposure is relevant to local side-effects, such as oropharyngeal candidiasis, dysphonia and coughing. Pharmacokinetic properties that influence the degree of systemic exposure are relevant to the pharmacodynamic effect of ICS-induced hypothalamic–pituitary–adrenal axis suppression and cortisol suppression, an indicator of potential long-term systemic side-effects, such as reduced growth velocity and bone density, fractures, and skin bruising and thinning.

Therefore, significant differences in the pharmacokinetic and pharmacodynamic characteristics of the currently available inhaled corticosteroids warrant careful consideration when used in clinical practice as they may result in differences in efficacy and local and systemic safety profiles.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the European Respiratory Society.